Macitentan

'macitentan) is an endothelin receptor antagonist. The chemical name of macitentan is N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N''- propylsulfamide. Macitentan is indicated for the treatment of Pulmonary Arterial Hypertension (PAH, WHO GROUP I) to delay disease progression.'

Brands

Adult Dose

Neonatal

Paedriatic

Characteristics

. It is of Synthetic origin. . The Molecular Weight of Macitentan is 588.27.

Contraindications

Macitentan

Effects

The symptomatic adverse reactions produced by Macitentan are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Pharyngitis, Bronchitis, Nasopharyngitis, influenza, urinary tract infection.

Indications

Interactions

No data regarding the interactions of Macitentan was found.

Interfrence

Risks

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Storage

Warnings

Other ERAs cause hepatotoxicity and liver failure. Obtain baseline liver enzymes and monitor as clinically indicated . Decreases in hemoglobin . Pulmonary edema in patients with pulmonary veno-occlusive disease. If confirmed, discontinue treatment. Decreases in sperm count have been observed in patients taking ERA.

Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.